# Long-term Effects of COVID-19

> **NCT05220514** · — · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 71 (actual)

## Conditions studied

- COVID-19
- SAR-CoV-2

## Interventions

- **DRUG:** (R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195)
- **DRUG:** 2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB)

## Key facts

- **NCT ID:** NCT05220514
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-19
- **Primary completion:** 2024-11-30
- **Final completion:** 2024-11-30
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2025-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05220514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05220514, "Long-term Effects of COVID-19". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT05220514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*